Nexalin Technology Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Nexalin Technology Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 3845 — Electromedical & Electrotherapeutic Apparatus
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Houston
- Headquarters state / province
- Texas
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- NXL
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001527352
- EIN
- 27-5566468
Board of directors
-
Alan Kazden · DirectorSince 2023
-
Ben Hu · DirectorSince 2022
-
David Owens · Director · Chief Medical OfficerSince 2023
-
Leslie Bernhard · DirectorSince 2024
-
Mark White · Director · CEOSince 2023
-
Rick Morad · DirectorSince 2022
Chief executives
Mark White
· President/CEO
Dates unknown
Director election results
Annual meeting of July 16, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
100.0%
-
100.0%
-
100.0%
-
100.0%
-
100.0%
Board connections
1 of this board's directors also sit on 2 other boards.
- via Leslie Bernhard
- via Leslie Bernhard
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 29, 2025 | Leonard Osser 10% owner | Grant or award | +83,333 | — | — |
| Sep 29, 2025 | David Owens Director, Officer (Chief Medical Officer) | Grant or award | +36,459 | — | — |
| Sep 29, 2025 | Ben Hu Director | Grant or award | +36,459 | — | — |
| Sep 29, 2025 | Alan Kazden Director | Grant or award | +36,459 | — | — |
| Mar 12, 2025 | Shelton Carolyn Hamby Officer (Sr. VP - Quality, Regulatory) | Open-market purchase | +6,000 | $2.20 | $13,200 |
| Feb 4, 2025 | David Owens Director, Officer (Chief Medical Officer) | Open-market purchase | +1,000 | $3.10 | $3,100 |
| Feb 4, 2025 | David Owens Director, Officer (Chief Medical Officer) | Open-market purchase | +1,000 | $2.98 | $2,980 |
| Jan 28, 2025 | David Owens Director, Officer (Chief Medical Officer) | Open-market purchase | +1,500 | $2.70 | $4,050 |
| Jan 23, 2025 | David Owens Director, Officer (Chief Medical Officer) | Open-market purchase | +1,000 | $2.70 | $2,700 |
| Jan 13, 2025 | David Owens Director, Officer (Chief Medical Officer) | Open-market purchase | +2,000 | $2.50 | $5,000 |
| Dec 20, 2024 | David Owens Director, Officer (Chief Medical Officer) | Open-market purchase | +1,000 | $2.75 | $2,750 |
| Oct 28, 2024 | David Owens Director, Officer (Chief Medical Officer) | Open-market purchase | +500 | $2.19 | $1,095 |
| Oct 14, 2024 | Shelton Carolyn Hamby Officer (Senior VP) | Open-market purchase | +24,000 | $0.85 | $20,400 |
| Sep 30, 2024 | Leslie Bernhard Director | Grant or award | +49,838 | — | — |
| Sep 30, 2024 | Ben Hu Director | Grant or award | +175,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.